On April 27th, He Jie, an academician of China Academy of Sciences and director of the National Cancer Center, made a response at the press conference, in view of the fact that there are sometimes over-indications and over-indications in the process of tumor treatment.

He Jie said that at present, the individual differences of cancer patients are obvious, and the treatment is also very complicated. At present, the consensus, guidelines and even standards of diagnosis and treatment based on limited medical evidence have not kept up with the development of medicine. The development of medicine is an exploratory science. Many standards, including international practices, were a few years ago, and now the situation has developed again. Therefore, the medical plan or written guidelines approved for drug indications are likely to be backward, so we should give patients some treatments beyond the indications or guidelines on the basis of sufficient clinical evidence to explore the diagnosis and treatment effects. In fact, many drugs are really effective after exceeding the indications.

He Jie emphasized that clinical pharmacology institutions and ethics committees should be strictly supervised. These clinical studies on over-indications and over-treatment guidelines are innovations in clinical treatment, not over-treatment, but under strict supervision. "Facts have also proved that many cancer patients can benefit from this situation." He Jie said.